Medtronic will promote Kweli Thompson to president of the company’s neuroscience portfolio. Thompson, who currently is president of Medtronic’s cardiac rhythm management business, will start the new role on June 1, according to a Monday securities filing.
The new job follows the planned departure of Brett Wall, the current neuroscience leader. Wall will stay on until Sept. 1 to help with the transition. Wall will receive severance benefits with his departure, according to the filing.
The leadership change also affects Medtronic’s diabetes spinoff, MiniMed. Wall notified MiniMed’s board on Sunday that he plans to resign as a board director in July. Scott Cundy, Medtronic’s chief quality, development and innovation officer, was appointed to MiniMed’s board on Monday.
BD names new head of interventional business
BD named Peter Menziuso president of its interventional business starting on June 1, the company announced Monday. Menziuso joins BD from Johnson & Johnson Vision, where he led a $5 billion business and was responsible for tasks including commercial operations, research and development, supply chain and quality.
Menziuso has more than 30 years of experience in global healthcare leadership. BD CEO Tom Polen touted Menziuso’s combination of strategic leadership and operational discipline in a statement.
Menziuso is expected to continue growing BD’s interventional business, which makes products for surgery, urology, critical care and treating peripheral vascular disease. According to BD’s latest quarterly results ending March 31, the interventional business brought in $1.36 billion in revenue, a 7.3% increase year over year.
